Article

Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance

2020-06-26

Abstract excerpt

<h4>Background</h4> Endocrine therapy is the most common treatment for estrogen receptor (ER)-positive breast cancer, but its effectiveness is limited by high rates of primary and acquired resistance. There are likely many genetic causes and recent studies suggest the important role of ESR1 mutations and fusions in endocrine resistance. Previously we reported a recurrent ESR1 fusion called ESR1-CCDC170 in 6-8%...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5e5a73df-dbea-5ff3-b406-d09754c8060f
DOI: 10.1101/2020.06.26.149948

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistanceDOI 10.1101/2020.06.26.149948Read

Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers.Semantic proximity Read

Elucidation of Novel Therapeutic Targets for Breast Cancer with ESR1-CCDC170 FusionSemantic proximity Read

The Prognostic and Predictive Value of ESR1 Fusion Gene Transcripts in Primary Breast CancerSemantic proximity Read

Characterization of ESR1 alterations in patients with breast and gynecologic cancers.Semantic proximity Read

The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancerSemantic proximity Read

Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications.Semantic proximity Read

<scp>Fusion‐associated</scp>carcinomas of the breast: Diagnostic, prognostic, and therapeutic significanceSemantic proximity Read

<i>ESR1</i> fusion proteins invoke breast cancer subtype-dependent enrichment of ligand independent pro-oncogenic signatures and phenotypesSemantic proximity Read

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.Semantic proximity Read

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.Semantic proximity Read

ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes.Semantic proximity Read

Molecular Characterization of ESR1 Variants in Breast CancerSemantic proximity Read